Britain and America have finalized a major trade agreement that will keep zero duties on British drug shipments going into the US market.
Agreement Details of the Accord
Under the terms of the agreement, the UK has pledged to boost expenditure on drugs through the public health system. This pledge secures that import taxes on these key products will stay at nothing for a timeframe of 36 months.
This deal comes after previous warnings to hike tariffs on patented drug imports, with potential rates floated up to one hundred percent.
"This agreement with the Britain bolsters the worldwide climate for innovative medicines and introduces much-needed balance to American-British medicine commerce," a statement declared.
Commercial Significance
Drugs represent one of the the United Kingdom's largest goods shipped to the US, which is easily the biggest destination for large UK drugmakers.
Trade data reveal that in the 12 months to the end of September, the UK shipped drugs worth over eleven billion pounds to the US. This value accounted for nearly one-fifth of British export trade in that period.
"This guarantee protects jobs, boosts funding and facilitates the UK to become a worldwide center for life sciences," a government official commented.
Specific British Pledges
The pact entails several specific commitments from the UK:
- Revised Affordability Limit: The UK will increase the price threshold at which it judges new medicines to be unaffordable by 25%.
- Increased NHS Spending: There is a goal to double overall NHS spending on treatments from 0.3 percent of GDP to 0.6 percent over the coming ten years.
- Refund Ceiling: The amount pharmaceutical firms must pay back to the NHS to prevent overspending will be limited at fifteen percent. Previously, repayments topped 20%.
Recent Tensions
The deal takes place against a protracted tension between the pharmaceutical industry and the British authorities over medicine costs and regulatory access.
The disagreement were exacerbated by claims that US patients were paying significantly more for the same drugs than patients in the other developed nations.
Recently, several major pharmaceutical investments in the UK have been halted or scrapped, while substantial investments have been directed toward US facilities.
The Science Minister stated that the NHS needed to spend more on drugs, noting that its expenditure on drugs had declined as a share of its total funding over the past decade.
